⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL976426 | 0.84 | PYGM (0.59) | — | |
| SCHEMBL2292834 | 0.82 | CHEK1 (0.65) | — | |
| SCHEMBL2292518 | 0.81 | SERPINE1 (0.71) | — | |
| SCHEMBL2025586 | 0.80 | MEN1 (0.72) | — | |
| SCHEMBL30466712 | 0.80 | MEN1 (0.72) | — | |
| SCHEMBL2330281 | 0.80 | MEN1 (0.69) | — | |
| SCHEMBL975250 | 0.77 | MAPT (0.53) | — | |
| SCHEMBL5147436 | 0.77 | PYGL (0.54) | — | |
| SCHEMBL10026584 | 0.76 | CHEK1 (1.00) | — | |
| SCHEMBL14075233 | 0.76 | DHODH (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598651-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | Sanofi-Aventis Deutschland GmbH (DE) | 2013-06-05 | — | — | EP | claimed |
| US-20130123360-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-05-16 | — | — | US | claimed |
| WO-2012013621-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-02-02 | — | — | WO | claimed |
| EP-2412819-A1 | Methods and uses relating to the identification of compound associated with bacterial infection | Sanofi-Aventis Deutschland GmbH (DE) | 2012-02-01 | — | — | EP | claimed |
| EP-2598651-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | Sanofi-Aventis Deutschland GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123360-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130123360-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| WO-2012013621-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
| EP-2412819-A1 | Methods and uses relating to the identification of compound associated with bacterial infection | Sanofi-Aventis Deutschland GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| EP-2412819-A1 | Methods and uses relating to the identification of compound associated with bacterial infection | Sanofi-Aventis Deutschland GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |